Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viet Nam Pharmaceutical - JSC's revenue for the
three
months ended in Mar. 2026 was ₫1,237,438 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₫5,654,456 Mil.
Viet Nam Pharmaceutical - JSC's Revenue per Share for the
three
months ended in Mar. 2026 was ₫5,221.26.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₫23,858.47.
During the past 7 years, Viet Nam Pharmaceutical - JSC's highest 3-Year average Revenue per Share Growth Rate was 4.30% per year. The lowest was -0.90% per year. And the median was 1.15% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Viet Nam Pharmaceutical - JSC Revenue Related Terms
Viet Nam Pharmaceutical - JSC Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Viet Nam Pharmaceutical - JSC's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viet Nam Pharmaceutical - JSC Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viet Nam Pharmaceutical - JSC's Revenue distribution charts can be found below:
* The bar in red indicates where Viet Nam Pharmaceutical - JSC's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₫5,654,456 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viet Nam Pharmaceutical - JSC (HSTC:DVN) has a Revenue of ₫5,654,456 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Viet Nam Pharmaceutical - JSC and its competitors.
Is Viet Nam Pharmaceutical - JSC's Revenue too high?
Viet Nam Pharmaceutical - JSC's current Revenue is ₫5,654,456 Mil. Overall, Viet Nam Pharmaceutical - JSC has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Viet Nam Pharmaceutical - JSC's Revenue compare to ZTS?
Viet Nam Pharmaceutical - JSC's Revenue of ₫5,654,456 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Viet Nam Pharmaceutical - JSC and its competitors. Viet Nam Pharmaceutical - JSC's current Revenue is ₫5,654,456 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viet Nam Pharmaceutical - JSC stock overvalued right now?
Based on GuruFocus' analysis, Viet Nam Pharmaceutical - JSC (HSTC:DVN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫22,083.68, compared to a current price of ₫18,800.00 — trading 14.9% below its estimated fair value. The current Revenue is ₫5,654,456 Mil. Viet Nam Pharmaceutical - JSC's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Viet Nam Pharmaceutical - JSC (HSTC:DVN), the current Revenue is ₫5,654,456 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viet Nam Pharmaceutical - JSC (HSTC:DVN) Overvalued in 2026?
Based on GuruFocus' analysis, Viet Nam Pharmaceutical - JSC stock appears to be undervalued.
The current stock price of ₫18,800.00 is trading 14.9% below its estimated GF Value™ of ₫22,083.68.
GuruFocus considers Viet Nam Pharmaceutical - JSC to be Modestly Undervalued.
Key valuation signals for HSTC:DVN:
Revenue: ₫5,654,456 Mil
GF Value™: ₫22,083.68 vs. price of ₫18,800.00 (14.9% below fair value)
No single metric tells the full story. See the HSTC:DVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viet Nam Pharmaceutical Corp - JSC is engaged in the manufacturing of drugs. The company provides testing services for drugs and medicinal ingredients.
80GF Score
Get the complete analysis for HSTC:DVN
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HSTC:DVN has been successfully added to your 
